



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



28 MAR 2022

**FDA ADVISORY**

No. 2022-0605-A

**TO: ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

**SUBJECT: Lifting the Advisory of FINECARE™ HBA1C TEST under FDA Advisory No. 2022-0605 entitled “Public Health Warning Against the Purchase and Use of Unregistered Medical Device Products”**

The Food and Drug Administration (FDA) informs all healthcare professionals and the general public that the warning against the purchase and use of FINECARE™ HBA1C TEST as mentioned in FDA Advisory No. 2022-0605 is hereby lifted.


Accordingly, the list released in FDA Advisory No. 2022-0605 is hereby updated to remove the abovementioned medical device.

The issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to existing laws, rules, and regulations.

For more information and inquiries, kindly contact the FDA Center for Device Regulation, Radiation Health, and Research through e-mail at [cdrrhr@fda.gov.ph](mailto:cdrrhr@fda.gov.ph) or call (02) 8857-1900 loc. 8301.

To report any sale or distribution of unnotified medical device, contact the online reporting facility, **eReport**, through e-mail at [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph).

Dissemination of this advisory to all concerned is hereby requested.

  
**DR. OSCAR G. GUTIERREZ, JR.**  
Officer-in-Charge Director General

DTN 20220121102333

